Search
Talmapimod
go.drugbank.com/drugs/DB05412InvestigationalTalmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.
Dovitinib
go.drugbank.com/drugs/DB05928InvestigationalDovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. … Chiron currently has three ongoing Phase I clinical trials for dovitinib.
FX06
go.drugbank.com/drugs/DB05685InvestigationalFX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development. It is being developed by Fibrex Medical Inc. … FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells.
Bevirimat
go.drugbank.com/drugs/DB06581InvestigationalBevirimat, also known as PA-457 or YK-FH312, is investigated in clinical trials for treating HIV infection. Bevirimat is a solid. … They also show profound effects on scalp and body hair in humans. Bevirimat targets the protein gag-pol polyprotein.
Niflumic acid
go.drugbank.com/drugs/DB04552InvestigationalNiflumic acid is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.
Lucanthone
go.drugbank.com/drugs/DB04967InvestigationalIt is currently being tested as a radiation sensitizer. … One of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel. (From Martindale The Extrapharmacopoeia, 30th ed., p46).
Nifedipine
go.drugbank.com/drugs/DB01115ApprovedInvestigational[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972. … [A190273] The most popular of the third generation dihydropyridines is [amlodipine].[A190273] Nifedipine was granted FDA approval on 31 December 1981.[L11383]
LGD-1550
go.drugbank.com/drugs/DB05785ExperimentalLGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.